Background: The clinical efficacy of autologous blood therapy (ABT) in patients with atopic dermatitis (AD) was demonstrated by a randomized double-blind placebo-controlled study. To characterize the blood component mediating the therapeutic efficacy of ABT for AD, we evaluated the clinical efficacy of autologous plasma therapy (APT) and autologous high-molecular-weight plasma protein fraction therapy (AHPT) in patients with AD in this study. Methods: A total of 22 patients with recalcitrant AD were treated with 8 weekly intramuscular injections of either autologous plasma (n = 11) or autologous high-molecular-weight plasma protein fraction (n = 11) for 7 weeks. Results: The clinical severity score of AD (SCORAD value) of11 patients who completed AHPT significantly decreased from 79.7 ± 17.0 (mean ± SD) at baseline to 65.8 ± 16.4 at 6 weeks and 60.1 ± 16.0 at 7 weeks (Wilcoxon signed-rank test, p < 0.05). There were no significant differences among the SCORAD values measured at baseline (74.2 ± 19.6), at 6 weeks (66.3 ± 23.6) and at 7 weeks (67.5 ± 20.8) in 10 patients who completed APT (p > 0.05). Conclusion: This result suggests that the blood component mediating the therapeutic efficacy of ABT in patients with AD might be present in the high-molecular-weight plasma protein fraction.

Journal Section:
Editor's choice
Keywords:
Atopic dermatitis, Autologous blood therapy, Autologous plasma therapy
1.
Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts-Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152-169.
[PubMed]
https://doi.org/10.1016/j.jaci.2006.03.045
2.
Novak N, Bieber T, Leung DY: Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003;112(suppl 6):128-139.
[PubMed]
https://doi.org/10.1016/j.jaci.2003.09.032
3.
Bieber T: Atopic dermatitis. N Engl J Med 2008;358:1483-1494.
[PubMed]
https://doi.org/10.1056/NEJMra074081
4.
Krathen RA, Hsu S: Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53:338-340.
[PubMed]
https://doi.org/10.1016/j.jaad.2005.02.014
5.
Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, Simpson E: Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007;56:222-227.
[PubMed]
https://doi.org/10.1016/j.jaad.2006.08.031
6.
Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU: Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122-128.
[PubMed]
https://doi.org/10.1016/j.jaci.2007.11.016
7.
Schafer T: Epidemiology of complementary alternative medicine for asthma and allergy in Europe and Germany. Ann Allergy Asthma Immunol 2004;93(suppl 1):5-10.
[PubMed]
https://doi.org/10.1016/S1081-1206(10)61481-0
8.
Pittler MH, Armstrong NC, Cox A, Collier PM, Hart A, Ernst E: Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. Br J Dermatol 2003;148:307-313.
[PubMed]
https://doi.org/10.1046/j.1365-2133.2003.04921.x
9.
Staubach P, Onnen K, Vonend A, Metz M, Siebenhaar F, Tschentscher I, Opper B, Magerl M, Ludtke R, Kromminga A, Maurer M: Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology 2006;212:150-159.
[PubMed]
https://doi.org/10.1159/000090656
10.
Bajaj AK, Saraswat A, Upadhyay A, Damisetty R, Dhar S: Autologous serum therapy in chronic urticaria: old wine in a new bottle. Indian J Dermatol Venereol Leprol 2008;74:109-113.
[PubMed]
https://doi.org/10.4103/0378-6323.39691
11.
Hanifin JM, Rajka G: Diagnostic features of atopic eczema. Acta Derm Venereol (Stockh) 1980;92(suppl):44-47.
12.
Narita YM, Hirahara K, Mizukawa Y, Kano Y, Shiohara T: Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy? J Dermatol 2011;38:236-245.
[PubMed]
https://doi.org/10.1111/j.1346-8138.2010.01154.x
13.
European Task Force on Atopic Dermatitis: Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993;186:23-31.
[PubMed]
https://doi.org/10.1159/000247298
14.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
[PubMed]
https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
15.
Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB: Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007;157:645-648.
[PubMed]
https://doi.org/10.1111/j.1365-2133.2007.08112.x
16.
Asefi M, Augustin M: Regulatory therapy: treatment with nonspecific stimulants in dermatology and modern perspective (in German). Forsch Komplementarmed 1999;6 (suppl 2):9-13.
[PubMed]
https://doi.org/10.1159/000057140
17.
Mori O, Hashimoto T: Autologous whole blood intramuscular injection as a cure for chronic urticaria: report of a patient in whom intradermal injection of autologous serum continued to cause a weal-and-flare response. Br J Dermatol 1999;140:1192-1193.
[PubMed]
18.
Wallmann J, Pali-Scholl I, Jensen-Jarolim E: Anti-ids in allergy: timeliness of a classic concept. World Allergy Organ J 2010;3:195-201.
[PubMed]
https://doi.org/10.1097/WOX.0b013e3181e61ebf
19.
Shoenfeld Y: The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med 2004;10:17-18.
[PubMed]
https://doi.org/10.1038/nm0104-17
© 2013 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2013
You do not currently have access to this content.